

<p>Adding a second antithrombotic drug to aspirin for long-term secondary prevention may be considered in patients with a moderate risk of ischaemic events and without a high bleeding risk.<sup>83,622,687–689</sup></p>	<b>IIb</b>	<b>A</b>
<p>ACE inhibitors (or ARB) are recommended if a patient has other conditions (e.g. HF, hypertension, or DM).<sup>622</sup></p>	<b>I</b>	<b>A</b>
<p>Beta-blockers are recommended in patients with LV dysfunction or systolic HF.<sup>622</sup></p>	<b>I</b>	<b>A</b>
<p>In patients with established ASCVD, oral lipid-lowering treatment with an ultimate LDL-C goal of &lt;1.4 mmol/L (55 mg/dL) and a <math>\geq 50\%</math> reduction in LDL-C vs. baseline is recommended.</p>	<b>I</b>	<b>A</b>

© ESC 2021